Stock screener

KYTX

Conviction 32HealthcareScan · Mon, Aug 10, 2026
KYTX$7.90-0.75%
ResistanceSupportVol 14
63 bars
Vol MA14 833.29K
May 11May 28Jun 16Jul 6Jul 23Aug 10
Kyverna Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.kyvernatx.com
Price7.90
Change-0.75%
Gap+0.13%
Rel volume2.36×
Avg volume959.92K
Avg $ vol7.28M
SMA 207.56
SMA 508.05
SMA 2008.29
Price vs 50-1.81%
Price vs 200-4.72%
MA stackbearish
50/200 crossdeath · 9d
Supertrenddown · 8.87
RSI (14)51
MACD hist0.08
MACD crossbull · 4d
Stoch %K / %D79 / 77
ADX (14)14
+DI / −DI20 / 17
RSI divergenceBullish
MACD divergenceBullish
ATR %+6.01%
ADR %5.60%
52w high11.25
52w low3.02
From 52w high-29.78%
Above 52w low+161.59%
New 52w highNo
SqueezeOn · 3d
Bollinger width13.30%
%B0.84
Donchian pos79.31%
Donchian high8.14
Donchian low6.98
AVWAP (52w high)8.78
vs AVWAP high-10.00%
AVWAP (52w low)8.30
vs AVWAP low-4.81%
OBV trendDown
Chaikin MF (20)-0.11
Today vs 20d2.36×
Avg vol (14d)833.29K
Avg vol (20d)959.92K
Avg $ vol (20d)7.28M
Market cap480.28M
RS 3m (vs SPY)-20.11%
RS 6m (vs SPY)-4.62%
RS line new highNo
Trend template3/8
Technical rank36.7
1 week+5.19%
1 month-6.89%
3 months-15.51%
6 months-0.38%
1 year+138.67%
YTD-9.92%
P/E-2.98
P/B2.46
P/S
P/FCF-3.12
EPS-3.64
Div yield
ROE-82.48%
ROA-62.76%
Debt/Eq
Current8.15
EV/EBITDA-2.67
Gross margin
Net margin
Rev growth
EPS growth-26.54%
Price target30.00
Target upside279.75%
Analyst ratingBuy
Institutional75.02%
Ent. value448.09M
Revenue
Net income-39.73M
Gross profit
Free cash flow-153.72M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out60.8M
Employees129
ListedThu, Feb 8, 2024
Free float35.7M
Float %59.1%
Short interest7.85M
Days to cover6.0d
Short volume39.2%
Squeeze score80 / 100
Next earnings
EPS forecast
Last EPS vs est−$0.66 vs −$0.75
Last surprise+12.0% beat
Setup gradeD
Conviction32 / 100
Pattern quality
Tech rank36.7 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction
Pattern family
Resistance9.77
Support7.04
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in KYTX

All disclosures →
No recent disclosed trades by Congress in KYTX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in KYTX · 7 buys · 1 sell

InsiderSideShares
CLARK IAN T
Director · Stock Option (right to buy) · 2026-05-27
Grant20.58K
SEIDENBERG BETH C
Director · Stock Option (right to buy) · 2026-05-27
Grant20.58K
Cohen Fred E
Director · Common Stock · 2026-05-27
Grant5.09K
Shaw Christi
Executive Chairperson · Common Stock · 2026-05-27
Tax4.19K
Aktar Mert
Director · Common Stock · 2026-05-27
Grant5.09K
Cohen Fred E
Director · Common Stock · 2026-05-27
Other
SEIDENBERG BETH C
Director · Common Stock · 2026-05-27
Other
Cohen Fred E
Director · Stock Option (right to buy) · 2026-05-27
Grant20.58K
Aktar Mert
Director · Stock Option (right to buy) · 2026-05-27
Grant20.58K
CLARK IAN T
Director · Common Stock · 2026-05-27
Grant5.09K

SEC filings

EDGAR filings in KYTX · 4 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.